By bridging redox regulation, proteostasis, mitochondrial quality control, and metabolic signaling, the HSP–HSF1–AMPK–SIRT1 axis emerges as a pivotal adaptive target to mitigate the progressive decline associated with SO and DS. The gene discussed is HSF1; the disease is Dravet syndrome.